JP2020531535A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020531535A5 JP2020531535A5 JP2020511435A JP2020511435A JP2020531535A5 JP 2020531535 A5 JP2020531535 A5 JP 2020531535A5 JP 2020511435 A JP2020511435 A JP 2020511435A JP 2020511435 A JP2020511435 A JP 2020511435A JP 2020531535 A5 JP2020531535 A5 JP 2020531535A5
- Authority
- JP
- Japan
- Prior art keywords
- hematopoietic
- cell population
- hematopoietic cell
- cells
- exon
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024076658A JP2024105479A (ja) | 2017-08-28 | 2024-05-09 | Ｃｄ３３標的剤と共に使用するためのｃｄ３３エクソン２欠損型ドナー幹細胞 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762551075P | 2017-08-28 | 2017-08-28 | |
| US62/551,075 | 2017-08-28 | ||
| PCT/US2018/048317 WO2019046285A1 (en) | 2017-08-28 | 2018-08-28 | CD33 EXON 2 DONOR STEM CELLS FOR USE WITH CD33 TARGETING AGENTS |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024076658A Division JP2024105479A (ja) | 2017-08-28 | 2024-05-09 | Ｃｄ３３標的剤と共に使用するためのｃｄ３３エクソン２欠損型ドナー幹細胞 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020531535A JP2020531535A (ja) | 2020-11-05 |
| JP2020531535A5 true JP2020531535A5 (https=) | 2021-09-30 |
Family
ID=65525985
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020511435A Pending JP2020531535A (ja) | 2017-08-28 | 2018-08-28 | Ｃｄ３３標的剤と共に使用するためのｃｄ３３エクソン２欠損型ドナー幹細胞 |
| JP2024076658A Pending JP2024105479A (ja) | 2017-08-28 | 2024-05-09 | Ｃｄ３３標的剤と共に使用するためのｃｄ３３エクソン２欠損型ドナー幹細胞 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024076658A Pending JP2024105479A (ja) | 2017-08-28 | 2024-05-09 | Ｃｄ３３標的剤と共に使用するためのｃｄ３３エクソン２欠損型ドナー幹細胞 |
Country Status (4)
| Country | Link |
|---|---|
| US (2) | US11718659B2 (https=) |
| EP (1) | EP3676372A4 (https=) |
| JP (2) | JP2020531535A (https=) |
| WO (1) | WO2019046285A1 (https=) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108290939B (zh) | 2015-10-16 | 2023-01-13 | 纽约市哥伦比亚大学理事会 | 用于抑制谱系特异性抗原的组合物和方法 |
| SG11201907870VA (en) | 2017-02-28 | 2019-09-27 | Vor Biopharma Inc | Compositions and methods for inhibition of lineage specific proteins |
| US11718659B2 (en) * | 2017-08-28 | 2023-08-08 | The Trustees Of Columbia University In The City Of New York | CD33 exon 2 deficient donor stem cells for use with CD33 targeting agents |
| CA3110837A1 (en) | 2018-08-28 | 2020-03-05 | Vor Biopharma Inc. | Genetically engineered hematopoietic stem cells and uses thereof |
| US11866494B2 (en) * | 2018-08-31 | 2024-01-09 | Innovative Cellular Therapeutics Holdings, Ltd. | CAR T therapy through uses of co-stimulation |
| MX2021008490A (es) * | 2019-01-16 | 2021-09-28 | Univ Columbia | Composiciones y metodos para la inhibicion de antigenos con especificidad de linaje. |
| CN114423865A (zh) * | 2019-05-23 | 2022-04-29 | Vor生物制药股份有限公司 | Cd33修饰的组合物和方法 |
| AU2020336211A1 (en) * | 2019-08-28 | 2022-03-10 | Vor Biopharma Inc. | Compositions and methods for CD123 modification |
| US20220290160A1 (en) | 2019-08-28 | 2022-09-15 | Vor Biopharma Inc. | Compositions and methods for cll1 modification |
| CA3153700A1 (en) | 2019-09-09 | 2021-03-18 | Scribe Therapeutics Inc. | Compositions and methods for use in immunotherapy |
| WO2021081244A1 (en) * | 2019-10-22 | 2021-04-29 | Fred Hutchinson Cancer Research Center | Base editor-mediated cd33 reduction to selectively protect therapeutic cells |
| CN116157135A (zh) * | 2020-06-03 | 2023-05-23 | 纽约市哥伦比亚大学理事会 | 使用基于crispr的碱基编辑器系统抑制谱系特异性抗原的组合物和方法 |
| US20240110189A1 (en) | 2020-08-28 | 2024-04-04 | Vor Biopharma Inc. | Compositions and methods for cll1 modification |
| US20240238344A1 (en) | 2020-08-28 | 2024-07-18 | Vor Biopharma Inc. | Compositions and methods for cd123 modification |
| JP2023541457A (ja) | 2020-09-14 | 2023-10-02 | ブイオーアール バイオファーマ インコーポレーテッド | Ｃｄ３８修飾のための化合物および方法 |
| WO2022056459A1 (en) | 2020-09-14 | 2022-03-17 | Vor Biopharma, Inc. | Compositions and methods for cd5 modification |
| WO2022061115A1 (en) | 2020-09-18 | 2022-03-24 | Vor Biopharma Inc. | Compositions and methods for cd7 modification |
| WO2022067240A1 (en) | 2020-09-28 | 2022-03-31 | Vor Biopharma, Inc. | Compositions and methods for cd6 modification |
| US20230364146A1 (en) | 2020-09-30 | 2023-11-16 | Vor Biopharma Inc. | Compositions and methods for cd30 gene modification |
| CA3199623A1 (en) * | 2020-10-27 | 2022-05-05 | Vor Biopharma Inc. | Compositions and methods for treating hematopoietic malignancy |
| WO2022094245A1 (en) | 2020-10-30 | 2022-05-05 | Vor Biopharma, Inc. | Compositions and methods for bcma modification |
| WO2022147347A1 (en) | 2020-12-31 | 2022-07-07 | Vor Biopharma Inc. | Compositions and methods for cd34 gene modification |
| CN115443333B (zh) * | 2021-04-27 | 2025-04-25 | 上海驯鹿生物技术有限公司 | 一种基因编辑的造血干细胞及其与car-t细胞的联合应用 |
| EP4330394A2 (en) * | 2021-04-28 | 2024-03-06 | Eisai R&D Management Co., Ltd. | Antisense oligonucleotides and their use for treatment of neurodegenerative disorders |
| CA3236152A1 (en) | 2021-11-09 | 2023-05-19 | Vor Biopharma Inc. | Compositions and methods for erm2 modification |
| WO2024015925A2 (en) | 2022-07-13 | 2024-01-18 | Vor Biopharma Inc. | Compositions and methods for artificial protospacer adjacent motif (pam) generation |
| EP4598588A1 (en) * | 2022-10-05 | 2025-08-13 | Musc Foundation for Research Development | Superantigen vaccine conjugate for the treatment of cancer |
| WO2024168312A1 (en) * | 2023-02-09 | 2024-08-15 | Vor Biopharma Inc. | Methods for treating hematopoietic malignancy |
| WO2025030010A1 (en) | 2023-08-01 | 2025-02-06 | Vor Biopharma Inc. | Compositions comprising genetically engineered hematopoietic stem cells and methods of use thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201913765YA (en) * | 2014-07-21 | 2020-03-30 | Novartis Ag | Treatment of cancer using a cd33 chimeric antigen receptor |
| US10201606B2 (en) | 2014-11-26 | 2019-02-12 | Miltenyi Biotec Gmbh | Combination immunotherapy of antigen-recognizing receptors and hematopoietic cells for the treatment of diseases |
| CN108290939B (zh) * | 2015-10-16 | 2023-01-13 | 纽约市哥伦比亚大学理事会 | 用于抑制谱系特异性抗原的组合物和方法 |
| WO2017177011A1 (en) * | 2016-04-06 | 2017-10-12 | University Of Florida Research Foundataion, Inc. | Biomarkers for anti-leukemic therapy |
| SG11201907870VA (en) * | 2017-02-28 | 2019-09-27 | Vor Biopharma Inc | Compositions and methods for inhibition of lineage specific proteins |
| US11718659B2 (en) * | 2017-08-28 | 2023-08-08 | The Trustees Of Columbia University In The City Of New York | CD33 exon 2 deficient donor stem cells for use with CD33 targeting agents |
-
2018
- 2018-08-28 US US16/640,086 patent/US11718659B2/en active Active
- 2018-08-28 EP EP18852123.1A patent/EP3676372A4/en active Pending
- 2018-08-28 JP JP2020511435A patent/JP2020531535A/ja active Pending
- 2018-08-28 WO PCT/US2018/048317 patent/WO2019046285A1/en not_active Ceased
-
2023
- 2023-06-06 US US18/206,269 patent/US20240166721A1/en not_active Abandoned
-
2024
- 2024-05-09 JP JP2024076658A patent/JP2024105479A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020531535A5 (https=) | ||
| JP2024105479A5 (https=) | ||
| Fidelle et al. | A microbiota-modulated checkpoint directs immunosuppressive intestinal T cells into cancers | |
| JP2020509050A5 (https=) | ||
| Hu et al. | The transcription factor c-Myb primes CD4+ CD8+ immature thymocytes for selection into the i NKT lineage | |
| Tseng et al. | Induction of split anergy conditions natural killer cells to promote differentiation of stem cells through cell–cell contact and secreted factors | |
| Wang et al. | Innate immune cells: A potential and promising cell population for treating osteosarcoma | |
| AU2025205147A1 (en) | Blockade of CD7 expression and chimeric antigen receptors for immunotherapy of T-cell malignancies | |
| Alfarra et al. | Targeting NK cell inhibitory receptors for precision multiple myeloma immunotherapy | |
| Zhao et al. | Switch receptor T3/28 improves long-term persistence and antitumor efficacy of CAR-T cells | |
| Jayaraman et al. | TIM3 mediates T cell exhaustion during Mycobacterium tuberculosis infection | |
| Leung | Infusions of allogeneic natural killer cells as cancer therapy | |
| Dong et al. | Essential function for SAP family adaptors in the surveillance of hematopoietic cells by natural killer cells | |
| JP2022066304A (ja) | Ｃａｒの抗腫瘍活性のための毒性管理 | |
| Yan et al. | Granulocyte colony-stimulating factor attenuates renal ischemia-reperfusion injury by inducing myeloid-derived suppressor cells | |
| BR112021007626A2 (pt) | Receptores antigênicos quiméricos específicos pa-ra receptor acoplado à proteína g receptor de classe c, grupo 5, membro d (gprc5d) | |
| KR20200029544A (ko) | 암 면역요법을 위해 면역 조절제와 조합된 면역조절 레티노이드 및 렉시노이드 화합물 | |
| Shin et al. | Transient expression of ZBTB32 in anti-viral CD8+ T cells limits the magnitude of the effector response and the generation of memory | |
| Polgárová et al. | Chimeric antigen receptor based cellular therapy for treatment of T-cell malignancies | |
| Kondo | Autologous hematopoietic stem cell transplantation for diffuse large B-cell lymphoma | |
| Cai et al. | Microtransplantation: clinical applications and mechanisms | |
| Meazza et al. | XLP 1 inhibitory effect by 2 B 4 does not affect DNAM‐1 and NKG 2 D activating pathways in NK cells | |
| Chen et al. | Immunotherapy for acute myeloid leukemia: current trends, challenges, and strategies | |
| Reuter et al. | Immunostimulation by OX40 ligand transgenic Ewing sarcoma cells | |
| Liu et al. | Recent advances of chimeric antigen receptor T‐cell therapy for acute myeloid leukemia |